medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Number 6

<< Back Next >>

Rev Invest Clin 2006; 58 (6)

Fluoroquinolone prophylaxis utility during chemoradiation induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City

Ugarte-Torres A, Villasis-Keever A, Hernández-Bribiesca ME, Crespo-Solis E, Ruiz-Palacios GM, Sifuentes-Osornio J, Ponce-de-León-Garduño A

Language: Spanish
References: 31
Page: 547-554
PDF size: 80.38 Kb.


ABSTRACT

Background. The use of fluoroquinolone prophylaxis in patients with cancer and neutropenia has failed to show a significant impact on mortality, despite its usefulness in reducing the incidence of gramnegative bacteremia. However, an increase in grampositive bacteremia and the emergence of resistant colonizing bacteria have consistently been noticed. Objective. To determine the impact of prophylaxis with fluoroquinolones on the incidence of bacteremia and mortality in a hospital with high fluorquinolone resistance in Mexico City. Patients. We conducted a retrospective and comparative study of patients with acute mieloid (AML) and hybrid (HL) leukemia who received or not prophylaxis with fluoroquinolones and who were attended from January 2000 to December 2003. We reviewed all pertinent clinical and laboratory data of the hematologic malignancies and the febrile episodes. Results. A total of 108 febrile episodes of severe neutropenia occurred in 69 patients, with an incidence of 6.5 events/1000 day-patient with neutropenia. The median age was 35 ± 18.3 years and 58% were men; 51 patients had AML (71.8%) and 20 (28.1%) HL. Prophylaxis had been given since the beginning of granulocytopenia in 46 (42.6%) febrile episodes (group 1), where as in 62 no prophylaxis was given (group 2). Of the 46 episodes with prophylaxis, 27 received ciprofloxacin 500 mg qd p.o. and 19, ciprofloxacin 500mg qd po plus fluconazol 100 mg qd po. The median duration of prophylaxis was 8.5 days (range 1-90 days). Twenty-nine bacteremias (26.8%) were documented, with an incidence of 16.4 bacteremias/1000 daypatient with neutropenia,12 (26%) in group 1 and 17 (27.5%) in group 2. Bacteremia was most frequently caused by gram negative organisms (18/29), being Escherichia coli (14) the most commonly isolated pathogen, with 7 episodes in each group. Eight (29.6%) of the 21 isolates in which fluoroquinolone susceptibility was tested were ciprofloxacin resistant, 3 in group 1 and 5 in group 2 (p= 0.58 ). Median survival of patients was 38 days in group 1 and 40 days in group 2. (p=0.2); mortality was similar in both groups, 34% and 27%, respectively. Conclusions. In a hospital with a high prevalence of fluoroquinoloneresistance, prophylaxis in patients with acute leukemia and severe neutropenia did not prevent febrile episodes and did not have any impact on mortality. However, there was no increase in infections caused by resistant bacteria.


REFERENCES

  1. Kerr K. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemotherapy 1999; 44: 587-91.

  2. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3030-51.

  3. Tattersshal M, Spiers A, Darrell J. Initial therapy with combination of five antibiotics in febrile patients with leukaemia and neutropaenia. Lancet 1972; 299: 162-6.

  4. Del Favero A, Menichetti F. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients. Eur J Cancer 1993; 29A (Suppl. 1): 2-6.

  5. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a metaanalysis. Clin Infect Dis 1996; 4: 795-805.

  6. Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol 2003; 21: 4127-37.

  7. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-87.

  8. Dejace P, Klastersky J. Emergence of resistance as a consequence of antimicrobial prophylaxis in immunocompromised patients. Scand J Infect Dis (Suppl.) 1986: 49: 165-71.

  9. Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis 2004; 39 (Suppl. 1): S7-S10.

  10. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.

  11. Kato M, Bautista A, Rolon M, et al. Increasing trend of antimicrobial drug-resistance in organisms causing bacteremia at a tertiarycare hospital: 1995 to 2000. Rev Invest Clin 2003; 55: 600-5.

  12. NCCLC. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard. Sixth edition. 2004, volume 23, number 2. M7-A6, p. M100-S14.

  13. van der Waaij D, Berghuis JM. Determination of the colonization resistance of the digestive tract of individual mice. J Hyg (Lond) 1974, 72: 379-87.

  14. Rozemberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective descontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis 1985, 152: 104-7.

  15. Maschmeyer G, Haralamble E, Gaus W, et al. Ciprofloxacin and norfloxacin for selective descontamination in patients with severe granulocytopenia. Infection 1988; 2: 98-104.

  16. Van der Auwera P, Gerain J. Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients. Drugs 1993; 45 (Suppl 3:) 81-90.

  17. Del Favero A, Menichetti F. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients. Eur J Cancer 1993; 29A (Suppl. 1): 2-6

  18. Cromer M, Akard L, Blanck, Allen S. Infection prevention in severly mielosuppressed patients: a comparison between ciprofloxacin and a regimen of selective antibiotic modulation of intestinal flora. Am M Med 1994; 4: 35-41.

  19. D’Antonio D, Piccolomini R, Iacone A, et al. Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1994; 4: 837-44.

  20. Bar W, Welling GW, Kurrie E. Effects of selective oral antimicrobial prophylaxis and systemic antibiotics on the fecal flora and betaaspartyglycine concentration in patients with acute leukemia. APMIS 1989; 8: 705-14.

  21. Brodsky AL, Minissale CJ, Melero MJ, Sanchez Avalos JC. Prophylaxis with fluoroquinolones in patients with neutropenia. Medicina (B Aires) 1993; 3: 401-7.

  22. Imrie K, Prince H, Couture F, Brandwein J, Keating A. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole. Bone Marrow Transpl 1995; 15: 267-70.

  23. Catarralá J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-60.

  24. Peña C, Albareda JM, Pallarés R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in blood stream infections. Antimicrob Agents Chemother 1995; 39: 520-4.

  25. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-8.

  26. Gómez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003; 97: 419-24.

  27. 27 Martino R, Subira M, Altés A, López R, Sureda A, Domingo- Albo A, Pericas R, S. Brunet. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia . A matched case-control study of the effect on infectious morbidity. Acta Haematol 1998; 99: 206–11.

  28. 28 Reuter S, Kern WV, Sigge A, Döhner H, Marre R, Kern P, von Baum H. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematological malignancies. Clin Infect Dis 2005; 40: 1087-93.

  29. Rubinstein E, Potgieter P, Davey P, Norrby SR. The use of fluoroquinolonas in neutropenic patients-analysis of adverse effects. J Antimicrob Chemother 1994; 34: 7-19.

  30. Bucaneve G, Micozzi A, Menichetti F, Martino P, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-87.

  31. Cullen M, Neil, S, Billingham L, Gaunt C, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 335: 988-98.




2020     |     www.medigraphic.com